Venable Fitzpatrick Secures Win for Novartis on Motion to Dismiss
October 27, 2022
October 27, 2022
WASHINGTON, Oct. 27 -- Venable, a law firm, issued the following news release:
On September 27, 2022, Venable Fitzpatrick secured a victory on behalf of Novartis Pharmaceuticals Corporation on a motion to dismiss certain defendants' counterclaims in patent litigation concerning Novartis's Entresto drug product.
In the motion, Novartis sought to dismiss declaratory judgment counterclaims filed by defendants Hetero and Torrent against three patents for which Het . . .
On September 27, 2022, Venable Fitzpatrick secured a victory on behalf of Novartis Pharmaceuticals Corporation on a motion to dismiss certain defendants' counterclaims in patent litigation concerning Novartis's Entresto drug product.
In the motion, Novartis sought to dismiss declaratory judgment counterclaims filed by defendants Hetero and Torrent against three patents for which Het . . .